BCL2 and posterior cortical atrophy: For PCa treatment, ASOs targeting Bcl-2 mRNA (Oblimersen- G3139) (NCT00085228) and Clusterin mRNA (Custirsen- OGX011) (NCT01188187) had been evaluated in PCa human patients in Phase II and III clinical trials, but both failed due to major toxic events or no significant survival improvement (Sternberg et al., 2009; Beer et al., 2017).